Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.

被引：13

作者：

Locke, Frederick Lundry

Ghobadi, Armin

Lekakis, Lazaros J.

Miklos, David Bernard

Jacobson, Caron A.

Jacobsen, Eric D.

Braunschweig, Ira

Oluwole, Olalekan O.

Siddiqi, Tanya

Lin, Yi

Reagan, Patrick Michael

Farooq, Umar

Deol, Abhinav

Bot, Adrian

Rossi, John M.

Jiang, Yizhou

Xue, Allen

Go, William Y.

Neelapu, Sattva Swarup

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Washington Univ, Sch Med, St Louis, MO USA

[3] Univ Miami Hlth Syst, Sylvester Comprehens Care Ctr, Miami, FL USA

[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA

[7] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[8] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[9] Mayo Clin, Rochester, MN USA

[10] Univ Rochester, Med Ctr, Rochester, NY 14642 USA

[11] Univ Iowa, Iowa City, IA USA

[12] Wayne State Univ, Karmanos Canc Ctr, Detroit, MI USA

[13] Kite, Santa Monica, CA USA

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.3039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3039

引用

页数：2

共 50 条

[21] ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) plus Utomilumab Patients with Refractory Large B Cell Lymphoma
Reshef, Ran
Miklos, David B.
Timmerman, John M.
Jacobson, Caron A.
Bennani, Nabila N.
Rossi, John M.
Sherman, Marika
Zheng, Lianqing
Sun, Jennifer
Palluconi, Gabrielle
Kim, Jenny J.
Jain, Michael D.
BLOOD, 2019, 134
[22] 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
Neelapu, Sattva S.
Ghobadi, Armin
Jacobson, Caron A.
Miklos, David B.
Lekakis, Lazaros J.
Oluwole, Olalekan O.
Lin, Yi
Braunschweig, Ira
Hill, Brian T.
Timmerman, John M.
Deol, Abhinav
Reagan, Patrick M.
Stiff, Patrick J.
Flinn, Ian W.
Farooq, Umar
Goy, Andre
McSweeney, Peter A.
Munoz, Javier
Siddiqi, Tanya
Chavez, Julio C.
Herrera, Alex F.
Xue, Allen
Jiang, Yizhou
Bot, Adrian
Rossi, John M.
Kim, Jenny J.
Go, William Y.
Locke, Frederick L.
BLOOD, 2018, 132
[23] 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
Neelapu, Sattva S.
Ghobadi, Armin
Jacobson, Caron A.
Miklos, David B.
Lekakis, Lazaros J.
Oluwole, Olalekan
Lin, Yi
Braunschweig, Ira
Hill, Brian T.
Timmerman, John
Deol, Abhinav
Reagan, Patrick M.
Stiff, Patrick
Flinn, Ian W.
Farooq, Umar
Goy, Andre
McSweeney, Peter A.
Munoz, Javier
Siddiqi, Tanya
Chavez, Julio C.
Herrera, Alex F.
Xue, Allen
Jiang, Yizhou
Bot, Adrian
Rossi, John M.
Kim, Jenny J.
Go, William Y.
Locke, Frederick L.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
[24] 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
Zhang, Muchen
Fang, Ying
Xu, Pengpeng
Cheng, Shu
Wang, Li
Zhao, Wei-Li
BLOOD, 2018, 132
[25] Durability of Response in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel in the Pivotal Phase 2 Study, ZUMA-1
Locke, Frederick L.
Ghobadi, Armin
Jacobson, Caron A.
Jacobsen, Eric
Miklos, David B.
Lekakis, Lazaros J.
Braunschweig, Ira
Oluwole, Olalekan O.
Lin, Yi
Siddiqi, Tanya
Deol, Abhinav
Reagan, Patrick M.
Farooq, Umar
Bot, Adrian
Jiang, Yizhou
Rossi, John M.
Xue, Allen
Go, William Y.
Neelapu, Sattva S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S277 - S278
[26] Durability of Response in ZUMA-1, the Pivotal Phase 2 Study of Axicabtagene Ciloleucel in Patients With Refractory Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 16 - 18
[27] ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL)
Kenderian, Saad S.
Oluwole, Olalekan O.
McCarthy, Philip L.
Reshef, Ran
Shiraz, Parveen
Ahmed, Omar
Le Gall, John
Nahas, Myrna
Tang, Lily
Neelapu, Sattva S.
BLOOD, 2020, 136
[28] Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): An Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-Cell Lymphoma from ZUMA-1
Neelapu, Sattva S.
Jacobson, Caron A.
Ghobadi, Armin
Miklos, David B.
Lekakis, Lazaros J.
Spooner, Clare
Kim, Jenny J.
Miao, Harry
Xue, Allen Xiaodong
Zheng, Yan
Locke, Frederick L.
BLOOD, 2023, 142
[29] A standardized comparison of outcomes in patients (pts) with refractory, aggressive non-hodgkin Lymphoma (rNHL) from the SCHOLAR-1 analysis and the ZUMA-1 study of axicabtagene ciloleucel (axi-cel)
Neelapu, S. S.
Locke, F. L.
Bartlett, N. L.
Lekakis, L. J.
Reagan, P. M.
Miklos, D.
Jacobson, C. A.
Braunschweig, I.
Oluwole, O.
Siddiqi, T.
Lin, Y.
Crump, M.
Kuruvilla, J.
Van den Neste, E.
Link, B. K.
Farooq, U.
Navale, L.
Go, W. Y.
Wiezorek, J.
Gisselbrecht, C.
ANNALS OF ONCOLOGY, 2017, 28
[30] Phase 1/2 primary analysis of ZUMA-6: Axicabtagene ciloleucel (Axi-Cel) in combination With atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL)
Jacobson, Caron A.
Westin, Jason R.
Miklos, David B.
Herrera, Alex F.
Lee, Jennifer
Seng, Judy
Rossi, John M.
Sun, Jennifer
Dong, Jinghui
Roberts, Zachary J.
Vezan, Remus
Avanzi, Mauro P.
Locke, Frederick L.
CANCER RESEARCH, 2020, 80 (16)

← 1 2 3 4 5 →